Effect of Rosuvastatin in patients of Chronic Obstuctive Airway Disease and Pulmonary Hypertensio
- Conditions
- Health Condition 1: null- chronic obstructive pulmonary disease with pulmonary arterial hypertension
- Registration Number
- CTRI/2012/12/003223
- Lead Sponsor
- KASTURBA MEDICAL COLLEGE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Patients of COPD [Criteria for diagnosis of COPD will be based on American Thoracic Society standards, with an FEV1 (forced expiratory volume in 1 second) <80% of the predicted values, and an FEV1 /FVC (forced vital capacity) ratio <70%] with routine echocardiography showing moderate pulmonary arterial hypertension.
Patients stable for at least 3 months
Patients with asthma, periodic wheezing,pulmonary embolism.
Inability to perform 6-minute walk test
Patients having liver diseases
Creatinine phosphokinase (CPK) >1.5 times the normal value.
Previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction.
History of transient ischemic attack or stroke within 3 months.
Pregnant or lactating women
Bleeding disorder
Patients on lipid lowering medications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method effect of rosuvastatin on pulmonary arterial hypertension3Timepoint: after 3 months of treatment
- Secondary Outcome Measures
Name Time Method effect of rosuvastatin on lung functions and quality of lifeTimepoint: after 3 months of enrolment